Company news
Regenxbio Inc. news in 2021
Regenxbio Inc.'s news releases, calls and decks from 2021, newest first.
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
November 21, 2021
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021
November 11, 2021
REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie
November 8, 2021
REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting
November 4, 2021
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
November 1, 2021
REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operational Highlights
October 25, 2021
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting
October 8, 2021
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
September 30, 2021
REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting
September 30, 2021
REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call
September 26, 2021
AbbVie and REGENXBIO Announce Eye Care Collaboration
September 12, 2021
Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors
September 6, 2021
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
August 8, 2021
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational Highlights
August 1, 2021
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting
May 13, 2021
REGENXBIO to Present at Upcoming Investor Conferences
May 5, 2021
REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights
May 4, 2021
REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights
April 27, 2021
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting
April 26, 2021
REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
April 20, 2021
REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome)
April 13, 2021
REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights
February 28, 2021
REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
February 21, 2021
REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD
February 15, 2021
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021
February 7, 2021
REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference
February 4, 2021
REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021
January 31, 2021
REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
January 11, 2021
REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 10, 2021
REGENXBIO Announces Pricing Of Public Offering Of Common Stock
January 7, 2021
REGENXBIO Announces Proposed Public Offering Of Common Stock
January 5, 2021
REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
January 4, 2021